Taina Sipponen

Taina Sipponen

Auto-generated profile, based on publicly available information

Taina Sipponen

Gastroenterology, Abdominal Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2012 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
PMPauliina Molander
Pauliina Molander
CBClas-Göran Af Björkesten
Clas-Göran Af Björkesten
HMHarri Mustonen
Harri Mustonen
JHJohanna Haapamäki
Johanna Haapamäki
MVMatti Vauhkonen
Matti Vauhkonen
TSTaina Sipponen
Taina Sipponen
Background. Fecal calprotectin (FC) concentration is a useful surrogate marker for mucosal healing (MH) during tumor necrosis factor alpha (TNFα)-blocki

23 February 2012 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
CBClas-Göran Af Björkesten
Clas-Göran Af Björkesten
UNUrpo Nieminen
Urpo Nieminen
UTUlla Turunen
Ulla Turunen
PAPerttu Arkkila
Perttu Arkkila
TSTaina Sipponen
Taina Sipponen
MFMartti Färkkilä
Martti Färkkilä
Objective. Endoscopically confirmed mucosal healing has become an important therapeutic goal in the treatment of Crohn's disease (CD). The role of clinical indices, such as the Crohn's disease activity index (CDAI) and the Harvey–Bradshaw index (HBI), and surrogate markers, such as C-reactive protein (CRP) and fecal calprotectin, to indicate remission determined by endoscopy needs to be clarified. We analyzed the role of surrogate markers and clinical indices, separately and in combination, by comparing them with endoscopically scored disease activity in biologically treated CD patients. Material and methods. Prospectively collected data of all patients with inflammatory bowel disease treated with tumor necrosis factor alpha antibodies in a tertiary center between 2007 and 2010. Altogether 210 endoscopies in 64 CD patients were analyzed. The simple endoscopic score for Crohn's disease (SES-CD) was used for scoring disease activity and compared with available data on concurrent CDAI, HBI, CRP, and calprotectin. Results. Endoscopic activity demonstrated a stronger correlation with calprotectin and CRP than with the clinical indices. Neither the clinical indices nor CRP was reliable at identifying endoscopic remission. However, calprotectin alone identified endoscopic remission with a sensitivity of 84% and specificity of 74%, but was beaten, although not statistically significantly, by a combined index, based on calprotectin and the HBI. Conclusions. Clinical scores commonly used in the assessment of disease activity are unreliable at differentiating endoscopic remission from active CD. Despite this, a score based on a combination of fecal calprotectin and the HBI is a new promising tool for identifying endoscopic remission.

19 December 2014 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
TSTaina Sipponen
Taina Sipponen
KKKaija-Leena Kolho
Kaija-Leena Kolho
The fecal neutrophil-derived biomarker calprotectin has several features of an ideal noninvasive test for detecting intestinal inflammation: it is simple, reliable, and low in cost. Its utility in differentiating inflammatory bowel diseases (IBDs) from functional conditions such as irritable bowel syndrome is well documented. Fecal calprotectin (FC) correlates closely with endoscopic activity of IBD. Emerging evidence suggest its usefulness in serial monitoring of disease activity and of therapy success in IBD. A low FC concentration predicts persistence of clinical remission especially in non-symptomatic ulcerative colitis and Crohn's colitis. Here, an overview is given to the current role of FC in diagnosis and clinical assessment of IBD.

1 December 2012 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
HLHeli J. Lehtonen
Heli J. Lehtonen
TSTaina Sipponen
Taina Sipponen
STSari Tojkander
Sari Tojkander
RKRiitta Karikoski
Riitta Karikoski
HJHeikki Järvinen
Heikki Järvinen
STSari Tuupanen
Sari Tuupanen

1 October 2013 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PMPauliina Molander
Pauliina Molander
TSTaina Sipponen
Taina Sipponen
HKHelena Kemppainen
Helena Kemppainen
AJAiri Jussila
Airi Jussila
TBTimo Blomster
Timo Blomster
MFMartti Färkkilä
Martti Färkkilä
Deep remission, meaning clinical remission with mucosal healing (MH), with anti-tumor necrosis factor-alpha (TNF-α) agents is a new target for therapy in inflammatory bowel disease (IBD). Our aim was to study how often patients on TNF-α blocking therapy actually achieve deep remission. The total of 252 IBD patients retrospectively included (183 Crohn's disease (CD), 62 ulcerative colitis (CU) or 7 inflammatory bowel disease unclassified-type colitis (IBDU)) received TNFα-antagonists (177 infliximab, 75 adalimumab) for at least 11 months and underwent ileocolonoscopy. We reviewed endoscopic and histological findings, clinical symptoms, C-reactive protein (CRP), and fecal calprotectin (FC) levels, and data on TNF-α blocking therapy. Defining deep remission as no clinical symptoms with endoscopic remission (the simple endoscopic score for Crohn's disease, SES-CD 0-2 or Mayo endoscopic subscore 0-1). Of the 252 patients, 168 (67%) were in clinical remission and 122 (48%) in deep remission after a median of 23 months of maintenance therapy. Of the 183 CD patients, 117 (64%) reached clinical remission and 79 (43%) deep remission. Of the UC patients, 52 (75%) were in clinical remission and 43 (62%) in deep remission. The majority of patients in deep remission (n=99, 81%) also had histologically inactive disease. Both median CRP and FC levels were significantly lower in patients with deep remission. Reassuringly, half of the IBD patients on the TNFα-blocking maintenance therapy achieved deep remission. The majority of patients in deep remission also achieved histological remission.

17 April 2012 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
TSTaina Sipponen
Taina Sipponen
JHJohanna Haapamäki
Johanna Haapamäki
ESErkki Savilahti
Erkki Savilahti
HAHenrik Alfthan
Henrik Alfthan
EHEsa Hämäläinen
Esa Hämäläinen
MFMartti Färkkilä
Martti Färkkilä
Objective. Data on fecal calprotectin and S100A12 in predicting wireless capsule endoscopy (WCE) findings in suspicion of Crohn's disease (CD) are scarce. Our aim was to study the role of calprotectin and S100A12 in predicting inflammatory lesions of small bowel in patients undergoing WCE. Material and methods. 84 patients undergoing WCE (77 for suspicion of CD and 7 CD patients for evaluation of disease extent) were prospectively recruited. WCE findings were scored. Patients provided a stool sample for measurements of biomarkers. Patients underwent an esophagogastroduodenoscopy and ileocolonoscopy before WCE. Results. WCE was abnormal in 35 (42%) of 84 patients: 14 patients with CD, 8 with NSAID enteropathies, 8 with angioectasias, 4 with polyps or tumors, and 1 with ischemic stricture. Median calprotectin concentration in the study population was 22 μg/g (range 2–342) and S100A12 concentration 0.048 μg/g (range 0.003–1.215). Fecal calprotectin was significantly higher in CD patients (median 91, range 2–312) compared with those with normal WCE or other abnormalities (p = 0.008), whereas fecal S100A12 (0.087 μg/g, range 0.008–0.896) did not differ between the groups (p = 0.166). In detecting inflammatory small bowel lesions, sensitivity, specificity, positive predictive value, and negative predictive value for fecal calprotectin (cutoff 50 μg/g) were 59%, 71%, 42%, and 83%, and for S100A12 (cutoff 0.06 μg/g) these were 59%, 66%, 38%, and 82%. Conclusions. In predicting small bowel inflammatory changes, fecal biomarkers calprotectin and S100A12 have moderate specificity, but low sensitivity. Neither fecal calprotectin nor S100A12 can be used for screening or excluding small bowel CD.